Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company ...

BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push ...

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Gibbons and Venable filed a patent infringement lawsuit on Sept. 18 in New Jersey District Court on behalf of Bausch & Lomb Inc. The court action, which targets PRN Physician Recommended ...

18 in New Jersey District Court on behalf of Bausch & Lomb Americas Inc. and other plaintiffs. The suit names Lipotriad LLC and PRN Physician Recommended Nutriceuticals for allegedly using the ...

Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to ...

Bausch Health (BHC) shares rallied 11.7% in the last trading session to close at $8.02. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

Bausch + Lomb is headed by Brent Saunders, a longtime pharmaceutical executive known for leading Allergan into a much-hyped but failed $160 billion merger with Pfizer Inc. (PFE) in 2015 and then ...